On Apr. 17, 2006, the National Cancer Institute announced initial results of the Study of Tamoxifen and Raloxifene, or STAR, showed that the drug raloxifene, used to prevent and treat osteoporosis in postmenopausal women, worked as well as tamoxifen in reducing breast cancer risk for postmenopausal women at increased risk of the disease.